Literature DB >> 19837616

A disproportion of TH1/TH2 cytokines with predominance of TH2, in urothelial carcinoma of bladder.

Abhigyan Satyam1, Prabhjot Singh, Nitika Badjatia, Amlesh Seth, Alpana Sharma.   

Abstract

OBJECTIVES: Bladder cancer is a common tumor of the urinary tract, accounting for 6% to 8% of all male malignancies and 2% to 3% of all female malignancies. Urothelial carcinoma (UC) of bladder is the second most common urologic malignancy after prostate cancer. Earlier report has elucidated immunologic unreactivity in cancer patients. Cytokines play a pivotal role in the induction of cell mediated and humoral immunity. Quantification of cytokine response in cancer patients can give significant insights about the cellular immunologic potency against the neoplastic cells. In the present study, we aimed to assess alterations of Th1 and Th2 derived cytokines in progression of UC of bladder by determining their circulatory concentration in bladder cancer patients and healthy controls and to correlate the observations with grade and severity of the disease.
MATERIALS AND METHODS: The study cohort consisted of 122 subjects; 72 patients with bladder UC (28, low grade; 17, high grade; 27, muscle invasive) and 50 healthy controls. The circulatory levels of various cytokines were measured using commercially available sandwich enzyme linked immunosorbent assay (ELISA) kit from BD Biosciences, San Diego, CA, and were statistically correlated according to the grade and the severity of disease.
RESULTS: The serum levels of typical Th1 cytokines: IL-2 and IFN-γ were found to be significantly lower (P < 0.001) while levels of Th2 cytokines i.e., IL-4, IL-5, and IL-10 were significantly higher (P < 0.001) in patients than in controls. The levels of all the cytokines were correlated with the grade and severity of the disease. There were significant differences between the patients with low grade tumors and muscle invasive tumors for all cytokines (P < 0.001); except IL-10 (P < 0.626).
CONCLUSIONS: The results of our study delineate that in bladder tumor patients a marked polarization exists towards the expression of Th2 type cytokines while Th1 remain suppressed. Furthermore, the levels of all the cytokines alter according to the grades of the tumor. This can give significant insights about the use of Th1 type cytokines for the administration of immunotherapy to bladder cancer patients. Development of new strategies attempting to manipulate the equilibrium between Th1 and Th2 cells would be beneficial in the management of UC of bladder in future.
Copyright © 2011 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19837616     DOI: 10.1016/j.urolonc.2009.06.002

Source DB:  PubMed          Journal:  Urol Oncol        ISSN: 1078-1439            Impact factor:   3.498


  15 in total

Review 1.  Immunological basis in the pathogenesis and treatment of bladder cancer.

Authors:  David B Thompson; Larry E Siref; Michael P Feloney; Ralph J Hauke; Devendra K Agrawal
Journal:  Expert Rev Clin Immunol       Date:  2014-11-13       Impact factor: 4.473

2.  Cytokine and cytokine receptor genes of the adaptive immune response are differentially associated with breast cancer risk in American women of African and European ancestry.

Authors:  Lei Quan; Zhihong Gong; Song Yao; Elisa V Bandera; Gary Zirpoli; Helena Hwang; Michelle Roberts; Gregory Ciupak; Warren Davis; Lara Sucheston; Karen Pawlish; Dana H Bovbjerg; Lina Jandorf; Citadel Cabasag; Jean-Gabriel Coignet; Christine B Ambrosone; Chi-Chen Hong
Journal:  Int J Cancer       Date:  2013-10-08       Impact factor: 7.396

3.  [Th1/Th2 and Treg/Th17 cell balance in peripheral blood of patients with ovarian cancer].

Authors:  Li-Hua Wang; Liang-Liang Wang; Jing Zhang; Pei Zhang; Sheng-Ze Li
Journal:  Nan Fang Yi Ke Da Xue Xue Bao       Date:  2017-08-20

4.  Targeting IL-5Rα with antibody-conjugates reveals a strategy for imaging and therapy for invasive bladder cancer.

Authors:  Michel Paquette; Luis-Guillermo Vilera-Perez; Simon Beaudoin; Nadia Ekindi-Ndongo; Pierre-Luc Boudreaut; Marc-Andre Bonin; Marie-Claude Battista; M'hamed Bentourkia; Angel F Lopez; Roger Lecomte; Eric Marsault; Brigitte Guérin; Robert Sabbagh; Jeffrey V Leyton
Journal:  Oncoimmunology       Date:  2017-05-19       Impact factor: 8.110

5.  Immune regulation of cancer.

Authors:  Mary L Disis
Journal:  J Clin Oncol       Date:  2010-06-01       Impact factor: 44.544

6.  BCG invokes superior STING-mediated innate immune response over radiotherapy in a carcinogen murine model of urothelial cancer.

Authors:  Aleksandar Obradovic; Alok Kumar Singh; Kara A Lombardo; James L Liu; Gregory Joice; Max Kates; William Bishai; David McConkey; Alcides Chaux; Marie-Lisa Eich; M Katayoon Rezaei; George J Netto; Charles G Drake; Phuoc Tran; Andres Matoso; Trinity J Bivalacqua
Journal:  J Pathol       Date:  2021-12-10       Impact factor: 7.996

7.  Comparing the Effects of Combined General/Epidural Anaesthesia and General Anaesthesia on Serum Cytokine Levels in Radical Cystectomy.

Authors:  Meltem Savran Karadeniz; Orkhan Mammadov; Hayriye Şentürk Çiftci; Sebahat Akgül Usta; Kamil Pembeci
Journal:  Turk J Anaesthesiol Reanim       Date:  2017-08-01

8.  Alterations of dendritic cell subsets and TH1/TH2 cytokines in the peripheral circulation of patients with superficial transitional cell carcinoma of the bladder.

Authors:  Feng Lang; Ma Linlin; Tian Ye; Zhang Yuhai
Journal:  J Clin Lab Anal       Date:  2012-09       Impact factor: 2.352

9.  Identification of pro-inflammatory cytokines associated with muscle invasive bladder cancer; the roles of IL-5, IL-20, and IL-28A.

Authors:  Se-Jung Lee; Eo-Jin Lee; Seon-Kyu Kim; Pildu Jeong; Young-Hwa Cho; Seok Joong Yun; Sangtae Kim; Gi-Young Kim; Yung Hyun Choi; Eun-Jong Cha; Wun-Jae Kim; Sung-Kwon Moon
Journal:  PLoS One       Date:  2012-09-04       Impact factor: 3.240

10.  Immunomodulatory effects of total intravenous and balanced inhalation anesthesia in patients with bladder cancer undergoing elective radical cystectomy: preliminary results.

Authors:  Maria Sofra; Paola Cordiali Fei; Luana Fabrizi; Maria Elena Marcelli; Claudia Claroni; Michele Gallucci; Fabrizio Ensoli; Ester Forastiere
Journal:  J Exp Clin Cancer Res       Date:  2013-02-03
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.